Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively.
Iovance: Earnings Review, Analysts Target Price and Upcoming SITC Data Release Tue, 07 Nov 2017 13:05:00 +0000 NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results Tue, 31 Oct 2017 20:01:00 +0000 SAN CARLOS, Calif., Oct. 31, 2017-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today reported its ...
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock Tue, 19 Sep 2017 20:35:42 +0000 SAN CARLOS, Calif., Sept. 19, 2017-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.